Introduction
Two insulin receptor mRNA transcripts resulting from alternative splicing of exon 11 in the receptor gene are expressed in a highly regulated tissue-specific fashion. To date, there is no information about the relative abundance of the protein isoforms encoded by these mRNAs in tissues of normal or diabetic subjects. We employed an antibody raised against the peptide sequence encoded by exon 11 to develop a specific immunoprecipitation assay that is capable of determining the fraction of receptors that include this amino acid sequence. The assay is based on the relative ability of the exon 11 specific monoclonal antibody (aIRa) compared to a nonspecific anti-receptor antiserum (B-2) to immunoprecipitate solubilized receptors that are first labeled with "25I-insulin. The assay was validated using standard curves generated with samples composed of known ratios of the two receptor isoforms. Our results in general confirm observations regarding the relative abundance of the two mRNA species in human tissues, with marked predominance of the exon 11 + isoform in liver, and the exon 11-isoform in leukocytes. Similar amounts of both variants are present in placenta, skeletal muscle, and adipose tissue. In studies with this assay using skeletal muscle extracts from control and noninsulin-dependent diabetes mellitus (NIDDM) subjects, as well as in studies of the two mRNAs in control versus NIDDM muscle using a quantitative polymerase chain reaction assay, we could find no significant difference between control and diabetic subjects. This data contradicts a recent report claiming that normal individuals have only the exon 11-mRNA transcript in their skeletal muscle, whereas NIDDM subjects have similar expression of both mRNAs. Given the emerging evidence that functional differences exist between the two receptor isoforms, these studies are relevant to our understanding of insulin receptor function in health and disease. (J. Clin. Invest. 1992 . 89:2066-2070.) Key words: insulin receptor * alternative splicing -non-insulin dependent diabetes mellitus.
We and others have recently shown that the mRNA that encodes the human insulin receptor is alternatively spliced in a tissue-specific manner (1-3). Thus, a small "cassette" exon (exon 1 1) encoding 12 amino acids at the carboxy-terminus of the extracellular receptor a-subunit is included (Exl1 +) or excluded (Ex 1 -) from the mature mRNA. As examples of this highly regulated process, liver expresses predominantly the Exl 1+ transcript, tissues such as cultured dermal fibroblasts and placenta express both mRNAs, and hematopoietic cells express only the Exl 1-transcript (1). The potential importance of this finding is underscored by the fact that the varying pattern of tissue-specific mRNA expression initially observed in humans is also precisely conserved in the rat (4). More importantly, emerging evidence indicates that the two encoded receptor isoforms are functionally distinct (3, 5, 6 A recent report claimed that an altered ratio of insulin receptor mRNA splice variants exists in skeletal muscle from patients with NIDDM (7). This study concluded that both mRNA transcripts are present in the muscle of diabetic subjects, but that only the Exl 1-transcript is present in the muscle of lean control subjects. In order to examine this crucial issue, we have assessed the relative abundance ofthe two receptor splice variants in skeletal muscle from normal subjects and patients with NIDDM at both the mRNA and protein levels.
surgery from normal subjects. Human placenta was obtained during a cesarian section performed on a normal subject. Samples of skeletal muscle (rectus abdominus) that were obtained from subjects previously characterized as lean normal, obese nondiabetic, and obese non-insulin-dependent diabetes mellitus (NIDDM)' (8) were kindly provided by Dr. Jose F. Caro (East Carolina University School ofMedicine, Greenville, NC). Total skeletal muscle (vastus lateralis) RNA samples that were prepared from muscle biopsies obtained from subjects previously characterized as lean normal and NIDDM (9) added to a final dilution of 1:200 followed by 1 h incubation at 4°C. Immunoprecipitates were collected, washed, and quantitated as described above.
Quantitative RNA-based polymerase chain reaction (PCR). Total RNA extracted from human placenta and transfected CHO cells as previously described (1) (1) . Insulin receptor cDNA was amplified in PCR reactions with primer sets A/B and C/B that included [a-32pJ-dCTP (3,000 Ci/mmol) as described (1) . 32P-labeled cDNA PCR products were separated by agarose gel electrophoresis followed by quantitation as described (1) .
Results
Validation of a quantitative immunoprecipitation assay. To study the relative expression and tissue distribution of the two alternatively spliced human insulin receptor isoforms at the protein level, we developed a quantitative immunoprecipitation assay using an exon 11-specific antibody (aIRa) and a nonspecific anti-insulin receptor antisera (B-2). Cell lysates prepared from CHO transfectants that overexpress exclusively the Ex 1 -or Ex 11 + insulin receptor were used as controls (5 For each experiment performed with human tissues, a standard curve was generated using samples composed of known varying ratios of CHO-Exl 1-and CHO-Exl 1 + cell lysates. As shown in Fig. 1 (CELL LYSATE) bined together at several fixed ratios followed by labeling with '25I-insulin and immunoprecipitation with either an exon 11-specific antibody (aIRa) or a non-specific anti-insulin receptor antisera (B-2). For each ratio tested, the total (B-2) immunoprecipitated cpm were equivalent (not shown).
The relative amount of lysate from CHO-Ex 1 I + cells (CHO 1 1+/ CHO Total) and the corresponding ratio of cpm immunoprecipitated with aIRa (cpm Exl l+)/total cpm immunoprecipitated with B-2 (cpm total) are shown. Each point is the mean (±SEM) of three determinations.
the two antibodies was determined, and the percentage ofinsulin receptors containing exon 11 was derived from the standard curve generated for each experiment. The relative abundance of Exl 1+ receptors differed between the tissues studied. As summarized in Table I , the pattern of tissue-specific protein isoform expression generally correlates with the characteristic tissue-specific pattern of expression for the two receptor mRNA transcripts (1) (2) (3) . In agreement with the absence of Ex 1 + mRNA in hematopoeitic cells, we were not able to detect any Exl 1 + receptor protein in leukocytes. Given the range of ratios tested in our standard curves, it is still possible that leukocytes do express Ex 1 + protein in very small amounts relative to the Ex 1-isoform.
In tissues where both receptor variants are expressed, our ability to accurately quantitate the relative abundance of the two isoforms is complicated by the small difference in insulin binding affinity (Exl 1-> Exl 1+) that is known to exist (3, 5) . Since receptors were labeled by binding to '25I-insulin, it is possible that our determination of the relative amount of Exl 1+ receptors was slightly lower than the actual abundance.
In a tissue such as muscle, where we calculate a value of -50% Ex 11 + receptors, the actual value would correct to 67% assuming a twofold difference in steady state tracer binding affinity. This factor may therefore account for the modest discrepancy between relative mRNA and protein expression that we have observed in tissues such as muscle or liver. Another factor that could contribute to this discrepancy in muscle is the fact that vastus lateralis was used for RNA studies, whereas rectus abdominus was used for studies of receptor protein.
Insulin receptor isoform expression in skeletal musclefrom NIDDM subjects. The relative expression of insulin receptor splice variants in skeletal muscle was determined at both the RNA and protein levels. Total RNA extracted from vastus lateralis skeletal muscle biopsies from lean normal (n = 7) and NIDDM (n = 5) subjects was reverse-transcribed followed by PCR-amplification of cDNA with two primer sets flanking exon 11 (A/B, C/B). As shown in the example presented in Fig.  2 , PCR with either primer set from all RNA samples resulted in two specific bands corresponding to the presence (721 bp with A/B, 300 bp with C/B) or absence ofexon 11 Fig. 3 . The mean of the percentage of Exl 1+ in lysates from lean normals was 39±5 compared to 47±6 for obese nondiabetics, and 49±7 for obese NIDDM subjects.
Discussion
Over the past 20 years, investigators have studied the role ofthe insulin receptor in mediating the important actions of insulin. Recently, it has become apparent that two receptor mRNA transcripts (containing or excluding exon I 1) are expressed at characteristic tissue-specific ratios as a result of alternative splicing (1) (2) (3) . To date, a limited functional assessment of the two encoded insulin receptor isoforms has been performed through parallel studies of transfected cell lines expressing either cDNA species (3, 5, 6, 12) . These studies reveal that although both receptor isoforms are active as tyrosine kinases and have the ability to signal various intracellular pathways (5, 12), the two receptors differ functionally in at least two ways. Thus, there are significant differences in ligand binding affinity (3, 5, 12) and the internalization kinetics of the two species differ as well (5, 6) . It is not known whether the two receptor proteins can be packaged as hybrid heterodimers or exist only as homodimers. In a situation where the steady state levels of the two mRNAs are equal, assuming that each transcript is translated with equal efficiency and that the turnover rate ofthe two proteins is comparable, random sorting ofhalf-receptors would be expected to result in a higher proportion of holoreceptors containing at least one Ex 1 + half-receptor. Using our current approach, we were not able to address these important issues. Additional studies will be required to directly assess the translation of the two transcripts, the turnover rate of the two proteins and the potential for receptor hybrid formation.
It is intriguing to speculate that changes in the relative expression of the two insulin receptor isoforms could somehow contribute to in vivo insulin resistance. Apart from several mutations in the insulin receptor gene which we and other groups have identified in patients with severe insulin resistance (13), little is known about the molecular basis for observed decreases in receptor number (14) and impairment ofinsulin-stimulated receptor autophosphorylation and/or tyrosine kinase activity (15) in tissues derived from human subjects with common insulin resistant states (obesity and NIDDM). Based on current knowledge, it seems unlikely that variation in the primary structure of the insulin receptor is common in patients with such disorders (16, 17) . Using a PCR approach, Mosthaf et al. have recently reported that skeletal muscle RNA from normal nondiabetic subjects contains only the Exl 1-mRNA transcript, whereas muscle RNA samples from NIDDM subjects contain both mRNA species (7) . This finding is at odds with our previous assessment of the abundance of the two mRNAs in skeletal muscle from two normal subjects (1), and with a prior report by Mosthaf et al., where two PCR products corresponding to the presence of both mRNAs in muscle from a normal subject are depicted (3).
We have now employed an RNA-based radiolabeled PCR product assay which we previously validated using standard curves to be quantitative over a range of known ratios of the two mRNA transcripts (1). Using two PCR primer sets, our current results again indicate that both mRNA transcripts are present (with Exl 1+ predominating) in skeletal muscle (vastus lateralis) obtained from a group of nondiabetic and NIDDM subjects. Moreover, the results with both primer sets agree, and we can detect no significant differences between NIDDM and control subjects. As a completely independent experimental approach to this issue, we analyzed the relative abundance of the two protein isoforms in skeletal muscle samples from another anatomic location (rectus abdominus), obtained from a different patient population. It is clear from our results that both receptor isoforms are expressed in the skeletal muscle of lean normals, obese nondiabetics, and obese diabetics. In addition, we were not able to detect significant differences in the relative abundance of receptor isoforms between the three groups ofsubjects tested. Further studies using a larger number of tissue samples will be needed to determine whether the slightly higher mean percentage of Exl 1+ receptors in obese nondiabetics and obese NIDDM evident in Fig. 3 represents a significant quantitative difference between these groups.
There are several potential explanations for the discrepancy between our findings and those reported by Mosthafet al. First, the source and condition of skeletal muscle differed in the two studies; we used biopsied vastus lateralis and rectus abdominus, whereas they studied samples of gastrocnemius obtained after limb amputation for vascular disease (7) . Second, their results are based on the use of a single PCR oligonucleotide primer set, and no standard curve with samples of varying known composition was reported to validate their PCR approach. It is possible that small differences between their control and NIDDM samples could have been markedly accentuated over 40 cycles of PCR by a difference in the efficiency with which each of the two competing cDNA templates were amplified. An internal standard curve is essential to rule out such a possibility.
In summary, several aspects of this study are worthy of note. First, using a new immunoprecipitation assay, we have provided the first available information, in any species, on the relative steady state expression of the two known protein isoforms of the insulin receptor in a variety of tissues (see note added in proof below). At first approximation, these data indicate that the tissue expression ofthe two proteins parallels earlier observations at the mRNA level. This is most obvious in tissues that display extreme variations at the mRNA level (e.g., liver and leukocytes), but also holds true in tissues with reasonable amounts of both transcripts, such as muscle and fat. Second, these data controvert the recent provocative observation of Mosthaf et al. (7) who noted a marked disparity between normal and NIDDM subjects with respect to the abundance of the two mRNA transcripts in muscle. Specifically, we have been unable to distinguish between controls and diabetics with respect to Ex 11+ receptor abundance at the mRNA level, which they assessed, or at the protein level. At this time, it cannot be answered whether the difference between these two studies represents heterogeneity of patient populations, the source and condition ofmuscle preparations, or the methodologies employed. Based on our data, we are confident that both normal and NIDDM subjects express similar amounts of the two receptor isoforms in the muscles that we have examined.
Future investigation will be required to identify potential subtle quantitative differences that might exist. Given the fact that the two receptor isoforms are functionally distinct, further pursuit of this issue may be warranted.
Note added in proof: Since the submission of this paper, a study by Sesti et al. (Diabetes. 41:6-11. 1992) was published that used human polyclonal anti-insulin receptor IgG to demonstrate that Ex I 1 + is the predominant receptor isoform present in human liver.
